Selected research
Industry Research
Rare Disease CRO Service Industry Research Report 2026
Market perspective
The global Rare Disease CRO Service market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Rare Disease CRO Service market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Rare Disease CRO Service market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Rare Disease CRO Service market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Rare Disease CRO Service include Precision for Medicine, Orphan-Reach, Medpace, Parexel, PPD, Worldwide Clinical Trials, AllStripes, LabCorp and Novotech, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Rare Disease CRO Service market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Rare Disease CRO Service.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Rare Disease CRO Service Market by Company
Precision for Medicine
Orphan-Reach
Medpace
Parexel
PPD
Worldwide Clinical Trials
AllStripes
LabCorp
Novotech
Syneos Health
Vial
Machaon Diagnostics
Caidya
Simbec Orion
Linical
MMS
Veristat
Celero
Rho
PROMETRIKA
Rare Disease CRO Service Segment by Type
Drug Development Strategy
Clinical Trial Management
Rare Disease CRO Service Segment by Application
Cardiovascular
Neuroscience
Ophthalmology
Others
Rare Disease CRO Service Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Rare Disease CRO Service market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Rare Disease CRO Service and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Rare Disease CRO Service.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Rare Disease CRO Service companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Drug Development Strategy
- Clinical Trial Management
Applications
- Cardiovascular
- Neuroscience
- Ophthalmology
- Others
Companies covered
- Precision for Medicine
- Orphan-Reach
- Medpace
- Parexel
- PPD
- Worldwide Clinical Trials
- AllStripes
- LabCorp
- Novotech
- Syneos Health
- Vial
- Machaon Diagnostics
- Caidya
- Simbec Orion
- Linical
- MMS
- Veristat
- Celero
- Rho
- PROMETRIKA
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Rare Disease CRO Service by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Drug Development Strategy
- 2.2.3 Clinical Trial Management
- 2.3 Rare Disease CRO Service by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Cardiovascular
- 2.3.3 Neuroscience
- 2.3.4 Ophthalmology
- 2.3.5 Others
- 2.4 Assumptions and Limitations
3 Rare Disease CRO Service Breakdown Data by Type
- 3.1 Global Rare Disease CRO Service Historic Market Size by Type (2021-2026)
- 3.2 Global Rare Disease CRO Service Forecasted Market Size by Type (2027-2032)
4 Rare Disease CRO Service Breakdown Data by Application
- 4.1 Global Rare Disease CRO Service Historic Market Size by Application (2021-2026)
- 4.2 Global Rare Disease CRO Service Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Rare Disease CRO Service Market Perspective (2021-2032)
- 5.2 Global Rare Disease CRO Service Growth Trends by Region
- 5.2.1 Global Rare Disease CRO Service Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Rare Disease CRO Service Historic Market Size by Region (2021-2026)
- 5.2.3 Rare Disease CRO Service Forecasted Market Size by Region (2027-2032)
- 5.3 Rare Disease CRO Service Market Dynamics
- 5.3.1 Rare Disease CRO Service Industry Trends
- 5.3.2 Rare Disease CRO Service Market Drivers
- 5.3.3 Rare Disease CRO Service Market Challenges
- 5.3.4 Rare Disease CRO Service Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Rare Disease CRO Service Players by Revenue
- 6.1.1 Global Top Rare Disease CRO Service Players by Revenue (2021-2026)
- 6.1.2 Global Rare Disease CRO Service Revenue Market Share by Players (2021-2026)
- 6.2 Global Rare Disease CRO Service Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Rare Disease CRO Service Head Office and Area Served
- 6.4 Global Rare Disease CRO Service Players, Product Type & Application
- 6.5 Global Rare Disease CRO Service Manufacturers Established Date
- 6.6 Global Rare Disease CRO Service Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Rare Disease CRO Service Market Size (2021-2032)
- 7.2 North America Rare Disease CRO Service Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Rare Disease CRO Service Market Size by Country (2021-2026)
- 7.4 North America Rare Disease CRO Service Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Rare Disease CRO Service Market Size (2021-2032)
- 8.2 Europe Rare Disease CRO Service Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Rare Disease CRO Service Market Size by Country (2021-2026)
- 8.4 Europe Rare Disease CRO Service Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Rare Disease CRO Service Market Size (2021-2032)
- 9.2 Asia-Pacific Rare Disease CRO Service Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Rare Disease CRO Service Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Rare Disease CRO Service Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Rare Disease CRO Service Market Size (2021-2032)
- 10.2 South America Rare Disease CRO Service Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Rare Disease CRO Service Market Size by Country (2021-2026)
- 10.4 South America Rare Disease CRO Service Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Rare Disease CRO Service Market Size (2021-2032)
- 11.2 Middle East & Africa Rare Disease CRO Service Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Rare Disease CRO Service Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Rare Disease CRO Service Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Precision for Medicine
- 12.1.1 Precision for Medicine Company Information
- 12.1.2 Precision for Medicine Business Overview
- 12.1.3 Precision for Medicine Revenue in Rare Disease CRO Service Business (2021-2026)
- 12.1.4 Precision for Medicine Rare Disease CRO Service Product Portfolio
- 12.1.5 Precision for Medicine Recent Developments
- 12.2 Orphan-Reach
- 12.2.1 Orphan-Reach Company Information
- 12.2.2 Orphan-Reach Business Overview
- 12.2.3 Orphan-Reach Revenue in Rare Disease CRO Service Business (2021-2026)
- 12.2.4 Orphan-Reach Rare Disease CRO Service Product Portfolio
- 12.2.5 Orphan-Reach Recent Developments
- 12.3 Medpace
- 12.3.1 Medpace Company Information
- 12.3.2 Medpace Business Overview
- 12.3.3 Medpace Revenue in Rare Disease CRO Service Business (2021-2026)
- 12.3.4 Medpace Rare Disease CRO Service Product Portfolio
- 12.3.5 Medpace Recent Developments
- 12.4 Parexel
- 12.4.1 Parexel Company Information
- 12.4.2 Parexel Business Overview
- 12.4.3 Parexel Revenue in Rare Disease CRO Service Business (2021-2026)
- 12.4.4 Parexel Rare Disease CRO Service Product Portfolio
- 12.4.5 Parexel Recent Developments
- 12.5 PPD
- 12.5.1 PPD Company Information
- 12.5.2 PPD Business Overview
- 12.5.3 PPD Revenue in Rare Disease CRO Service Business (2021-2026)
- 12.5.4 PPD Rare Disease CRO Service Product Portfolio
- 12.5.5 PPD Recent Developments
- 12.6 Worldwide Clinical Trials
- 12.6.1 Worldwide Clinical Trials Company Information
- 12.6.2 Worldwide Clinical Trials Business Overview
- 12.6.3 Worldwide Clinical Trials Revenue in Rare Disease CRO Service Business (2021-2026)
- 12.6.4 Worldwide Clinical Trials Rare Disease CRO Service Product Portfolio
- 12.6.5 Worldwide Clinical Trials Recent Developments
- 12.7 AllStripes
- 12.7.1 AllStripes Company Information
- 12.7.2 AllStripes Business Overview
- 12.7.3 AllStripes Revenue in Rare Disease CRO Service Business (2021-2026)
- 12.7.4 AllStripes Rare Disease CRO Service Product Portfolio
- 12.7.5 AllStripes Recent Developments
- 12.8 LabCorp
- 12.8.1 LabCorp Company Information
- 12.8.2 LabCorp Business Overview
- 12.8.3 LabCorp Revenue in Rare Disease CRO Service Business (2021-2026)
- 12.8.4 LabCorp Rare Disease CRO Service Product Portfolio
- 12.8.5 LabCorp Recent Developments
- 12.9 Novotech
- 12.9.1 Novotech Company Information
- 12.9.2 Novotech Business Overview
- 12.9.3 Novotech Revenue in Rare Disease CRO Service Business (2021-2026)
- 12.9.4 Novotech Rare Disease CRO Service Product Portfolio
- 12.9.5 Novotech Recent Developments
- 12.10 Syneos Health
- 12.10.1 Syneos Health Company Information
- 12.10.2 Syneos Health Business Overview
- 12.10.3 Syneos Health Revenue in Rare Disease CRO Service Business (2021-2026)
- 12.10.4 Syneos Health Rare Disease CRO Service Product Portfolio
- 12.10.5 Syneos Health Recent Developments
- 12.11 Vial
- 12.11.1 Vial Company Information
- 12.11.2 Vial Business Overview
- 12.11.3 Vial Revenue in Rare Disease CRO Service Business (2021-2026)
- 12.11.4 Vial Rare Disease CRO Service Product Portfolio
- 12.11.5 Vial Recent Developments
- 12.12 Machaon Diagnostics
- 12.12.1 Machaon Diagnostics Company Information
- 12.12.2 Machaon Diagnostics Business Overview
- 12.12.3 Machaon Diagnostics Revenue in Rare Disease CRO Service Business (2021-2026)
- 12.12.4 Machaon Diagnostics Rare Disease CRO Service Product Portfolio
- 12.12.5 Machaon Diagnostics Recent Developments
- 12.13 Caidya
- 12.13.1 Caidya Company Information
- 12.13.2 Caidya Business Overview
- 12.13.3 Caidya Revenue in Rare Disease CRO Service Business (2021-2026)
- 12.13.4 Caidya Rare Disease CRO Service Product Portfolio
- 12.13.5 Caidya Recent Developments
- 12.14 Simbec Orion
- 12.14.1 Simbec Orion Company Information
- 12.14.2 Simbec Orion Business Overview
- 12.14.3 Simbec Orion Revenue in Rare Disease CRO Service Business (2021-2026)
- 12.14.4 Simbec Orion Rare Disease CRO Service Product Portfolio
- 12.14.5 Simbec Orion Recent Developments
- 12.15 Linical
- 12.15.1 Linical Company Information
- 12.15.2 Linical Business Overview
- 12.15.3 Linical Revenue in Rare Disease CRO Service Business (2021-2026)
- 12.15.4 Linical Rare Disease CRO Service Product Portfolio
- 12.15.5 Linical Recent Developments
- 12.16 MMS
- 12.16.1 MMS Company Information
- 12.16.2 MMS Business Overview
- 12.16.3 MMS Revenue in Rare Disease CRO Service Business (2021-2026)
- 12.16.4 MMS Rare Disease CRO Service Product Portfolio
- 12.16.5 MMS Recent Developments
- 12.17 Veristat
- 12.17.1 Veristat Company Information
- 12.17.2 Veristat Business Overview
- 12.17.3 Veristat Revenue in Rare Disease CRO Service Business (2021-2026)
- 12.17.4 Veristat Rare Disease CRO Service Product Portfolio
- 12.17.5 Veristat Recent Developments
- 12.18 Celero
- 12.18.1 Celero Company Information
- 12.18.2 Celero Business Overview
- 12.18.3 Celero Revenue in Rare Disease CRO Service Business (2021-2026)
- 12.18.4 Celero Rare Disease CRO Service Product Portfolio
- 12.18.5 Celero Recent Developments
- 12.19 Rho
- 12.19.1 Rho Company Information
- 12.19.2 Rho Business Overview
- 12.19.3 Rho Revenue in Rare Disease CRO Service Business (2021-2026)
- 12.19.4 Rho Rare Disease CRO Service Product Portfolio
- 12.19.5 Rho Recent Developments
- 12.20 PROMETRIKA
- 12.20.1 PROMETRIKA Company Information
- 12.20.2 PROMETRIKA Business Overview
- 12.20.3 PROMETRIKA Revenue in Rare Disease CRO Service Business (2021-2026)
- 12.20.4 PROMETRIKA Rare Disease CRO Service Product Portfolio
- 12.20.5 PROMETRIKA Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst